SANUWAVE Health (SNWV) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 10, 2016
Document Information [Line Items]
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	1,417,663
Trading Symbol	snwv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		105,013,421
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK
Undesignated Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK
Cash and cash equivalents	122,948	152,930
Accounts receivable, net of allowance for doubtful accounts of $14,576 in 2016 and $8,963 in 2015	97,154	74,454
Inventory	230,906	284,908
Prepaid expenses	97,823	123,988
TOTAL CURRENT ASSETS	548,831	636,280
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation	2,555	4,228
OTHER ASSETS	11,141	11,097
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 4)	153,378	306,756
TOTAL ASSETS	715,905	958,361
Accounts payable	458,277	509,266
Accrued expenses (Note 5)	295,823	359,374
Accrued employee compensation	408,939	241,542
Interest payable, related parties (Note 6)	108,224	239,803
Promissory notes payable (Note 7)	115,933
Warrant liability (Note 11)	119,900	138,100
TOTAL CURRENT LIABILITIES	1,507,096	1,488,085
Notes payable, related parties (Note 6)	5,334,234	5,348,112
TOTAL LIABILITIES	6,841,330	6,836,197
COMMITMENTS AND CONTINGENCIES (Note 12)	0	0
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 104,178,421 and 63,056,519 issued and outstanding in 2016 and 2015, respectively (Note 9)	104,178	63,057
ADDITIONAL PAID-IN CAPITAL	89,647,379	87,086,677
ACCUMULATED DEFICIT	(95,841,107)	(92,994,408)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(35,875)	(33,162)
TOTAL STOCKHOLDERS' DEFICIT	(6,125,425)	(5,877,836)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 715,905	$ 958,361

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	6,175	6,175
Preferred stock, shares issued (in shares)	6,175	6,175
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	293	293
Preferred stock, shares issued (in shares)	293	293
Preferred stock, shares outstanding (in shares)	293	0
Undesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	4,993,532	4,993,532
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Accounts receivable, allowance for doubtful accounts	$ 14,576	$ 8,963
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	104,178,421	63,056,519
Common stock, outstanding (in shares)	104,178,421	63,056,519

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
REVENUES	$ 203,406	$ 239,983	$ 472,730	$ 450,435
COST OF REVENUES	77,988	75,779	151,169	134,597
GROSS PROFIT	125,418	164,204	321,561	315,838
OPERATING EXPENSES
Research and development	476,167	456,789	786,122	1,091,412
General and administrative	589,896	636,570	1,089,028	1,202,862
Depreciation	837	925	1,673	1,850
Amortization of Intangible Assets	76,689	76,689	153,378	153,378
TOTAL OPERATING EXPENSES	1,143,589	1,170,973	2,030,201	2,449,502
OPERATING LOSS	(1,018,171)	(1,006,769)	(1,708,640)	(2,133,664)
OTHER INCOME (EXPENSE)
Gain on sale of assets			1,000
Gain(loss) on warrant valuation adjustment (Note 11)	28,250	(429,311)	(769,447)	(373,285)
Interest expense, net	(110,557)	(81,636)	(264,744)	(160,980)
Amortization of debt issuance costs	(12,999)		(87,548)
Amortization of debt discount	(5,778)		(11,472)	(951)
Loss on foreign currency exchange	(2,868)	(3,817)	(5,848)	(12,719)
TOTAL OTHER EXPENSE	(103,952)	(514,764)	(1,138,059)	(546,984)
NET LOSS	(1,122,123)	(1,521,533)	(2,846,699)	(2,680,648)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	(5,684)	(768)	(2,713)	(13,486)
TOTAL COMPREHENSIVE LOSS	$ (1,127,807)	$ (1,522,301)	$ (2,849,412)	$ (2,694,134)
LOSS PER SHARE:
Net loss - basic and diluted (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.04)
Weighted average shares outstanding - basic and diluted (in shares)	102,645,697	63,056,519	88,933,089	62,993,885

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent	$ (2,846,699)	$ (2,680,648)
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Amortization of Intangible Assets	153,378	153,378
Depreciation	1,673	1,850
Change in allowance for doubtful accounts	5,613	(3,099)
Stock-based compensation - employees, directors and advisors	116,550	50,062
Loss on warrant valuation adjustment	769,447	373,285
Loss on conversion option of promissory notes payable	75,422
Gain on sale of property and equipment	(1,000)
Amortization of debt issuance costs	87,548
Amortization of debt discount	11,472	951
Changes in assets - (increase)/decrease
Accounts receivable - trade	(28,313)	40,995
Inventory	54,002	3,731
Prepaid expenses	26,165	(16,904)
Other	(44)	(180)
Changes in liabilities - increase/(decrease)
Accounts payable	(50,989)	53,688
Accrued expenses	(63,551)	(19,654)
Accrued employee compensation	167,397	125,583
Interest payable, related parties	(131,579)	(896)
Promissory notes payable - accrued interest	(77,615)
NET CASH USED BY OPERATING ACTIVITIES	(1,731,124)	(1,917,858)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of property and equipment	1,000
NET CASH PROVIDED BY INVESTING ACTIVITIES	1,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 2016 Equity Offering, net	1,596,855
Proceeds from Convertible Debt	106,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,702,855
EFFECT OF EXCHANGE RATES ON CASH	(2,713)	(13,486)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(29,982)	(1,931,344)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	152,930	3,547,071
CASH AND CASH EQUIVALENTS, END OF PERIOD	122,948	1,615,727
SUPPLEMENTAL INFORMATION
Cash paid for interest, related parties	$ 392,516	$ 161,936

Note 1 - Nature of the Business

Note 1 - Nature of the Business	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of the Business SANUWAVE Health, Inc. and subsidiaries (the “Company”) is an acoustic pressure shock wave technology company using a patented system of noninvasive, high-energy, acoustic pressure shock waves for indications such as regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE ® de novo The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE ® In addition to healthcare uses, our high-energy, acoustic pressure shock waves, due to their powerful pressure gradients and localized cavitational effects, may have applications in secondary and tertiary oil exploitation, for cleaning industrial waters, for sterilizing food liquids and finally for maintenance of industrial installations by disrupting biofilms formation. Our business approach will be through licensing and/or partnership opportunities.

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Going Concern The Company does not currently generate significant recurring revenue and will require additional capital during the second and third quarter of 2016. As of June 30, 2016, the Company had an accumulated deficit of $95,841,107 and cash and cash equivalents of $122,948 . For the six months ended June 30, 2016 and 2015, the net cash used by operating activities was $1,731,124 and $1,917,858, respectively. The Company incurred a net loss of $2,846,699 for the six months ended June 30, 2016 and a net loss of $4,810,285 for the year ended December 31, 2015. The operating losses create an uncertainty about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon raising additional capital during the third quarter of 2016 to fund operations. Management’s plans are to obtain additional capital in 2016 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3 Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2016 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements. Significant Accounting Policies For further information and a summary of significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016. Recently Issued Accounting Standards New accounting pronouncements are issued by the Financial Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued guidance to simplify several aspects of the accounting for share-based payments transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 31, 2016. Early adoption is permitted for an entity in an interim or annual period. We are currently evaluating the effect that the updated standard will have on our financial statements, but expect the guidance will add modest volatility in our equity-based compensation expense, provision for income taxes, and net income (loss).

Note 4 - Intangible Assets

Note 4 - Intangible Assets	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	4 . Intangible assets Intangible assets consist of the following: June 30, 2016 December 31, 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,348,757 ) (3,195,379 ) Net intangible assets $ 153,378 $ 306,756 The aggregate amortization charged to operations was $76,689 for the three months ended June 30, 2016 and 2015 and $153,378 for the six months ended June 30, 2016 and 2015.

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5 . Accrued expenses Accrued expenses consist of the following: June 30, 2016 December 31, 2015 Accrued former executive payment $ 100,000 $ 100,000 Accrued audit and tax preparation 46,752 93,500 Accrued directors and advisors fees 45,333 - Accrued outside services 43,105 58,813 Accrued legal professional fees 30,500 76,500 Accrued clinical study expenses 13,650 22,777 Accrued other 16,483 7,784 $ 295,823 $ 359,374

Note 6 - Notes Payable, Related

Note 6 - Notes Payable, Related Parties	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6 . Notes payable, related parties The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest is paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal was due August 1, 2015. On June 15, 2015, the Company and HealthTronics, Inc. entered into an amendment (the “Note Amendment”) to amend certain provisions of the notes payable, related parties. The Note Amendment provides for the extension of the due date to January 31, 2017. In the period ending March, 31, 2016, the Company reclassified the outstanding principal balance from non-current liabilities to current liabilities. I n connection with the Note Amendment, the Company entered into a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. The notes payable, related parties will bear interest at 8% per annum effective August 1, 2015 and during any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. On June 28, 2016, the Company and HealthTronics, Inc. entered into a second amendment (the “Second Amendment”) to amend certain provisions of the notes payable, related parties. The Second Amendment provides for the extension of the due date to January 31, 2018. The notes payable, related parties had an aggregate outstanding principal balance of $5,334,234, net of $38,509 debt discount at June 30, 2016 and $5,348,112, net of $24,631 debt discount at December 31, 2015, respectively. In addition, the Company, in connection with the Note Amendment, issued to HealthTronics, Inc. on June 15, 2015, an aggregate total of 3,310,000 warrants (the “Class K Warrants”) to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), at an exercise price of $0.55 per share, subject to certain anti-dilution protection. Each Class K Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after ten years. In addition, the Company, in connection with the Second Amendment, issued to HealthTronics, Inc. on June 28, 2016, an additional 1,890,000 Class K Warrants to purchase shares of the Company’s Common Stock at an exercise price of $0.08 per share, subject to certain anti-dilution protection. The exercise price of the 3,310,000 Class K Warrants issued on June 15, 2015 was decreased to $0.08 per share. Accrued interest currently payable totaled $108,224 and $239,803 at June 30, 2016 and December 31, 2015, respectively. Interest expense on notes payable, related parties totaled $108,224 and $80,968 for the three months ended June 30, 2016 and 2015, respectively, and $260,937 and $161,039 for the six months ended June 30, 2016 and 2015, respectively.

Note 7 - Promissory Notes Payab

Note 7 - Promissory Notes Payable	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Promissory notes payable On February 1, 2016, the Company entered into a financing transaction for the sale of an 8% Convertible Promissory Note (the “$58,300 Convertible Note”) and warrants (the “Class M Warrants”) in the principal amount of $58,300 each, with gross proceeds of $50,000 to the Company after payment of a 10% original issue discount and related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The Company did not utilize any form of general solicitation or general advertising in connection with the offering. The $58,300 Convertible Note was offered and sold to two accredited investors, with gross proceeds of $106,000 to the Company. The $58,300 Convertible Note and Class M Warrants were issued pursuant to the terms of a purchase agreement among the Company and the Investors. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on August 1, 2016. The Company has the right to prepay the convertible note and accrued interest during the first sixty (60) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days. Each Class M Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on February 21, 2021. The $58,300 Convertible Note is convertible, at any time from the issuance date, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 30% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the date of the purchase agreement or (ii) the voluntary conversion date. The $58,300 Convertible Note contained put options that may require the Company to repay the debt before its maturity. The $58,300 Convertible Note holder has rights to demand repayment in the event of defaults. However, since the put is contingent on an event of default, and no principal is due until maturity, the likelihood of the other default provision is considered to be very remote especially given the term of the $58,300 Convertible Note is six months. The promissory notes payable had an aggregate outstanding principal balance of $115,933, net of $4,473 debt issuance costs at June 30, 2016.

Note 8 - Income Taxes

Note 8 - Income Taxes	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8 . Income taxes The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2006. At June 30, 2016, the Company had federal net operating loss (“NOL”) carryforwards of $70,096,802 for tax years through the year ended December 31, 2015, that will begin to expire in 2025. The use of deferred tax assets, including federal net operating losses, is limited to future taxable earnings. Based on the required analysis of future taxable income under the provisions of ASC 740, Income Taxes The Company’s ability to use its NOL carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its NOL carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which NOL carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its NOL carryforwards for federal income tax purposes.

Note 9 - Equity Transactions

Note 9 - Equity Transactions	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Equity transactions 2016 Equity Offering On March 11, 2016, April 6, 2016, and April 15, 2016 in conjunction with an equity offering of securities (the “2016 Equity Offering”) with select accredited investors, the Company issued an aggregate of 25,495,835, 3,083,334 and 1,437,501, respectively, shares of common stock for an aggregate purchase price of $1,529,750, $185,000, and $86,200, respectively. The mandatory prepayment of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company was waived by HealthTronics, Inc. for this 2016 Equity Offering. The Company, in connection with the 2016 Equity Offering, issued to the investors an aggregate of 30,016,670 warrants (the “Class L Warrants”) to purchase shares of common stock at an exercise price of $0.08 per share. Each Class L Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on March 17, 2019. Pursuant to the terms of a Registration Rights Agreement that the Company entered with the investors in connection with the 2016 Equity Offering, the Company is required to file a registration statement that covers the shares of common stock and the shares of common stock issuable upon exercise of the Class L Warrants. The registration statement was declared effective by the SEC on February 16, 2016. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 2016 Equity Offering of $100,000. At the closing of the 2016 Equity Offering , the Company paid Newport Coast Securities, Inc., the placement agent for the equity offering, cash compensation based on the gross proceeds of the private placement and 3,001,667 Class L Warrants. Series A Warrant Conversion On January 13, 2016, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with certain beneficial owners (the “Investors”) of Series A warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pursuant to which the Investors exchanged (the “Exchange”) all of their respective Warrants for either (i) shares of Common Stock or (ii) shares of Common Stock and shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Preferred Stock”). The Exchange was based on the following exchange ratio (the “Exchange Ratio”): 1 Series A Warrant = 0.4685 shares of capital stock. Investors who, as a result of the Exchange, owned in excess of 9.99% (the “Ownership Threshold”) of the outstanding Common Stock, received a mixture of Common Stock and shares of Preferred Stock. They received Common Stock up to the Ownership Threshold, and received shares of Preferred Stock beyond the Ownership Threshold (but the total shares of Common Stock and Preferred Stock issued to such holders was still based on the same Exchange Ratio). The relative rights, preferences, privileges and limitations of the Preferred Stock are as set forth in the Company’s Certificate of Designation of Series B Convertible Preferred Stock, which was filed with the Secretary of State of the State of Nevada on January 12, 2016 (the “Series B Certificate of Designation”). In the Exchange an aggregate number of 23,701,428 Warrants were exchanged for 7,447,954 shares of Common Stock and 293 shares of Preferred Stock. Pursuant to the Series B Certificate of Designation, each of the Preferred Stock shares is convertible into shares of Common Stock at an initial rate of 1 Preferred Stock share for 12,500 Common Stock shares, which conversion rate is subject to further adjustment as set forth in the Series B Certificate of Designation. Pursuant to the terms of the Series B Certificate of Designation, the holders of the Preferred Stock shares will generally be entitled to that number of votes as is equal to the number of shares of Common Stock into which the Preferred Stock may be converted as of the record date of such vote or consent, subject to the Beneficial Ownership Limitation. In connection with entering into the Exchange Agreement, the Company also entered into a Registration Rights Agreement, dated January 13, 2016, with the Investors. The Registration Rights Agreement requires that the Company file with the SEC a registration statement to register for resale the shares of the Common Stock issued in connection with the Exchange and the Common Stock issuable upon conversion of the Preferred Stock shares (the “Preferred Stock Conversion Shares”). The registration statement was declared effective by the SEC on February 16, 2016.

Note 10 - Preferred Stock

Note 10 - Preferred Stock	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	10 . Preferred Stock The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On January 12, 2016, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series B Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 293 shares of preferred stock, par value $0.001 per share, as Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock has a stated value of $1,000 per share. On January 13, 2016, in connection with the Series A Warrant Conversion, the Company issued 293 shares of Series B Convertible Preferred Stock (for a more detailed discussion regarding the Series A Warrant Conversion, see Note 9). Under the Certificate of Designation, holders of Series B Convertible Preferred Stock are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. Such holders will participate on an equal basis per-share with holders of common stock in any distribution upon winding up, dissolution, or liquidation of the Company. Holders of Series B Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). Holders of the Series B Convertible Preferred Stock are entitled to vote on all matters affecting the holders of the common stock on an “as converted” basis, provided that such holder shall only vote such shares of Series B Convertible Preferred Stock eligible for conversion without exceeding the Beneficial Ownership Limitation. On April 29, 2016, the holders of Series B Convertible Preferred Stock converted the outstanding 293 shares of Series B Convertible Preferred Stock into 3,657,278 shares of common stock. As of April 29, 2016, there were no outstanding shares of Series B Convertible Preferred Stock. On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share. On March 17, 2014, in connection with a Private Placement, the Company issued 6,175 shares of Series A Convertible Preferred Stock. As of January 6, 2015 there were no outstanding shares of Series A Convertible Preferred Stock.

Note 11 - Warrants

Note 11 - Warrants	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Warrants [Text Block]	11 . Warrants A summary of the warrant activity as of June 30, 2016 and December 31, 2015, and the changes during the six months ended June 30, 2016, is presented as follows: Warrant class Outstanding as of December 31, 2015 Issued Exercised Converted Expired Outstanding as of June 30, 2016 Class E Warrants 3,576,737 - - - (3,576,737 ) - Class F Warrants 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 4,012,289 - - - 4,641,667 Class K Warrants 3,310,000 1,890,000 - - - 5,200,000 Class L Warrants - 33,018,337 - - - 33,018,337 Class M Warrants - 1,943,333 - - - 1,943,333 Series A Warrants 25,951,421 - - (23,701,427 ) - 2,249,994 38,302,686 40,863,959 - (23,701,427 ) (3,576,737 ) 51,888,481 SANUWAVE HEALTH, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2016 11 . Warrants (continued) A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.06 February 2019 Class K Warrants $ 0.08 June 2025 Class L Warrants $ 0.08 March 2019 Class M Warrants $ 0.06 February 2021 Series A Warrants $ 0.06 March 2019 The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The exercise price of the Class J Warrants, Class K Warrants, Class M and the Series A Warrants are subject to a “down-round” anti-dilution adjustment if the Company issues or is deemed to have issued certain securities at a price lower than the then applicable exercise price of the warrants. The exercise price of the Series A, Class J and Class M Warrants was adjusted to $0.06 due to the 2016 Equity Offering (see Note 9). The Class J Warrants and Class K Warrants may be exercised on a physical settlement or on a cashless basis. The Series A Warrants may be exercised on a physical settlement basis if a registration statement underlying the warrants is effective. If a registration statement is not effective (or the prospectus contained therein is not available for use) for the resale by the holder of the Series A Warrants, then the holder may exercise the warrants on a cashless basis. The Class J Warrants, the Class K Warrants, the Class M Warrants, the Series A Warrants and the Series B Warrants are derivative financial instruments. The estimated fair value of the Class J Warrants at the date of grant was $12,776. The related debt discount was accreted to interest expense through the maturity date of the related note. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which will be accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair value of the Class M Warrants at the date of grant was $9,091 and the estimated value of the conversion option of the note at the date of grant was $66,331. The related debt discount was accreted to interest expense through the maturity date of the related note. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. The Series B Warrants expired unexercised in March 2015. SANUWAVE HEALTH, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2016 11 . Warrants (continued) The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants, the volatility of the Company’s common stock price, and the risk-free interest rate. In addition, as of the valuation dates, management assessed the probabilities of future financing and other re-pricing events in the binominal valuation models. A summary of the changes in the warrant liability as of June 30, 2016 and December 31, 2015, and the changes during the three and six months ended June 30, 2016, is presented as follows: Class J Warrants Class K Warrants Class M Warrants Series A Warrants Total Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ 138,100 Issued - - 75,422 - 75,422 Change in fair value 17,600 (6,600 ) 878 (102,600 ) (90,722 ) Warrant liability as of March 31, 2016 $ 20,500 $ 16,100 $ 76,300 $ 9,900 $ 122,800 Issued - 25,350 - - 25,350 Change in fair value (6,600 ) (16,150 ) (2,400 ) (3,100 ) (28,250 ) Warrant liability as of June 30, 2016 $ 13,900 $ 25,300 $ 73,900 $ 6,800 $ 119,900

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12 . Commitments and contingencies Operating Leases Rent expense for the three months ended June 30, 2016 and 2015, was $40,455 and $38,505, respectively and for the six months ended June 30, 2016 and 2015, was $82,974 and $71,912, respectively. Litigation The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note 13 - Stock-based Compensat

Note 13 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	13 . Stoc k-based compensation On June 16, 2016, the Company granted to the active employees, members of the board of directors and two members of the Company’s Medical Advisory Board options to purchase 3,300,000 shares each of the Company’s common stock at an exercise price of $0.04 per share and vested upon issuance. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.0335 resulting in compensation expense of $110,550. Compensation cost was recognized upon grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the six months ended June 30, 2016 and 2015: 2016 2015 Weighted average expected life in years 5.0 5.5 Weighted average risk free interest rate 1.10 % 2.41 % Weighted average volatility 140.0 % 136.1 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 % T he Company recognized as compensation cost for all outstanding stock options granted to employees, directors and advisors, $112,050 and $22,235 for the three months ended June 30, 2016 and 2015, respectively and $116,550 and $50,062 for the six months ended June 30, 2016 and 2015, respectively. A summary of option activity as of June 30, 2016 and December 31, 2015, and the changes during the three and six months ended June 30, 2016, is presented as follows: Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 10,073,385 $ 0.62 Granted - $ - Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 10,073,385 $ 0.55 Granted 3,300,000 $ 0.04 Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of June 30, 2016 13,373,385 $ - Exercisable 13,273,385 $ 0.43 The range of exercise prices for options was $0.04 to $2.00 for options outstanding at June 30, 2016 and December 31, 2015. The aggregate intrinsic value for all vested and exercisable options was $0 at June 30, 2016 and December 31, 2015. The weighted average remaining contractual term for outstanding exercisable stock options was 7.63 and 7.46 years as of June 30, 2016 and December 31, 2015, respectively. A summary of the Company’s nonvested options as of June 30, 2016 and December 31, 2015, and changes during the three and six months ended June 30, 2016, is presented as follows: Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 175,002 $ 0.36 Granted - $ - Vested - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 175,002 $ 0.36 Granted 3,300,000 $ 0.04 Vested (3,375,002 ) $ 0.05 Cancelled - $ - Forfeited or expired - $ - Outstanding as of June 30, 2016 100,000 $ 0.21

Note 14 - Earnings (Loss) Per S

Note 14 - Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	14 . Earnings (loss) per share The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the six months ended June 30, 2016 and 2015, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 65,261,866 shares and 45,609,516 shares at June 30, 2016 and 2015, respectively.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent events Convertible Debentures On July 29, 2016, the Company entered into a financing transaction for the sale of a Convertible Debenture (the “Debenture”) in the principal amount of up to $500,000, with gross proceeds of $450,000 to the Company after payment of a 10% original issue discount. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The Company did not utilize any form of general solicitation or general advertising in connection with the offering. The Debenture was offered and sold to one accredited investor. The Debenture was issued pursuant to the terms of a purchase agreement among the Company and the Investor. The Debenture is secured by the accounts receivable of the Company and, unless earlier redeemed, matures on the third anniversary date of issuance. The Company shall pay to Investor a non-accountable fee (the “Commitment Fee”) of (i) Two Thousand Five Hundred and 00/100 Dollars ($2,500.00) and (ii) Eight Hundred Thirty Five Thousand (835,000) shares of Restricted Stock for Investor’s expenses and analysis performed in connection with the analysis of the Company and the propriety of the Investor’s making the contemplated investment. The Commitment Fee shall be paid on the signing closing date immediately upon receipt of the signing purchase price if Investory does not withhold such amounts from the signing purchase price. The Investor is entitled to, at any time or from time to time, commencing on the date that is one hundred fifty one (151) days from the issuance date set forth to convert the Conversion Amount (as defined below) into Conversion Shares, at a conversion price for each share of Common Stock (the “Conversion Price”) equal to either (i) if the Company is DWAC Operational at the time of conversion, Seventy percent (70%) of the lowest closing bid price (as reported by Bloomberg LP) of Common Stock for the twenty (20) Trading Days immediately preceding the date of the date of conversion of the Debentures, or (ii) if either the Company is not DWAC Operational or the Common Stock is traded on the bottom tier OTC Pink (or, “pink sheets”) at the time of conversion, Sixty Five percent (65%) of the lowest closing bid price (as reported by Bloomberg LP) of the Common Stock for the twenty (20) Trading Days immediately preceding the date of conversion of the Debentures, subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. The Company shall issue irrevocable instructions to its Transfer Agent regarding conversions such that the transfer agent shall be authorized and instructed to issue Conversion Shares upon its receipt of a Notice of Conversion without further approval or authorization from the Company. For purposes of this Debenture, the “Conversion Amount” shall mean the sum of (A) all or any portion of the outstanding Principal Amount of this Debenture, as designated by the Holder upon exercise of its right of conversion plus (B) any interest, pursuant to Section 10 or otherwise, that has accrued on the portion of the Principal Amount that has been designated for payment pursuant to (A). The Debenture may be called for redemption by the Company, upon not more than two (2) days written notice, for an amount (the “Redemption Price”) equal to: (i) if the Redemption Date (as defined below) is ninety (90) days or less from the date of issuance of this Debenture, One Hundred Five percent (105%) of the sum of the Principal Amount so redeemed plus accrued interest, if any; (ii) if the Redemption Date is greater than or equal to ninety one (91) days from the date of issuance of this Debenture and less than or equal to one hundred twenty (120) days from the date of issuance of this Debenture, One Hundred Fifteen percent (115%) of the sum of the Principal Amount so redeemed plus accrued interest, if any; (iii) if the Redemption Date is greater than or equal to one hundred twenty one (121) days from the date of issuance of this Debenture and less than or equal to one hundred fifty (150) days from the date of issuance of this Debenture, One Hundred Twenty percent (120%) of the sum of the Principal Amount so redeemed plus accrued interest, if any; (iv) if the Redemption Date is greater than or equal to one hundred fifty one (151) days from the date of issuance of this Debenture and less than or equal to one hundred eighty (180) days from the date of issuance of this Debenture, One Hundred Thirty percent (130%) of the sum of the Principal Amount so redeemed plus accrued interest, if any; and (v) if either (1) the Debentures are in default but the Holder consents to the redemption notwithstanding such default or (2) the Redemption Date is greater than or equal to one hundred eighty one (181) days from the date of issuance of this Debenture, one hundred forty percent (140%) of the sum of the Principal Amount so redeemed plus accrued interest, if any. The date upon which the Debentures are redeemed and paid shall be referred to as the “Redemption Date” (and, in the case of multiple redemptions of less than the entire outstanding Principal Amount, each such date shall be a Redemption Date with respect to the corresponding redemption). On July 29, 2016, the Company received gross proceeds of $175,000 from the Convertible Debenture, which is the first tranche of principal amount of $200,000, net of the $20,000 original debt discount, the $2,500 Commitment Fee and $2,500 in legal fees. $58,300 Convertible Note Repayment In August 2016, the Company repaid the $58,300 Convertible Note to both accredited investors in full, with accrued interest and a prepayment penalty of 140% of the total outstanding balance. 2016 Private Placement On August 11, 2016, opened a private placement of securities (the “2016 Private Placement”) with select accredited investors. The 2016 Private Placement is offering Units (the “Units”) at a purchase price of $0.06 per Unit, with each Unit consisting of (i) one (1) share of our common stock, $0.001 par value (the “Common Stock”) and, (ii) one (1) detachable warrant (the “Warrants”) to purchase one (1) share of our Common Stock at an exercise price of $0.08 per share. The Company and the accredited investors are executing and delivering this 2016 Private Placement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act Pursuant to the terms of a Registration Rights Agreement that the Company entered with the accredited investors in connection with the 2016 Private Placement, the Company is required to file a registration statement that covers the shares of Common Stock and the shares of common stock issuable upon exercise of the Warrants. The failure on the part of the Company to satisfy certain deadlines described in the Registration Rights Agreement may subject the Company to payment of certain monetary penalties. The Company has collected $130,000 to date from accredited investors.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2016 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards New accounting pronouncements are issued by the Financial Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued guidance to simplify several aspects of the accounting for share-based payments transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 31, 2016. Early adoption is permitted for an entity in an interim or annual period. We are currently evaluating the effect that the updated standard will have on our financial statements, but expect the guidance will add modest volatility in our equity-based compensation expense, provision for income taxes, and net income (loss).

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2016 December 31, 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,348,757 ) (3,195,379 ) Net intangible assets $ 153,378 $ 306,756

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2016 December 31, 2015 Accrued former executive payment $ 100,000 $ 100,000 Accrued audit and tax preparation 46,752 93,500 Accrued directors and advisors fees 45,333 - Accrued outside services 43,105 58,813 Accrued legal professional fees 30,500 76,500 Accrued clinical study expenses 13,650 22,777 Accrued other 16,483 7,784 $ 295,823 $ 359,374

Note 11 - Warrants (Tables)

Note 11 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant class Outstanding as of December 31, 2015 Issued Exercised Converted Expired Outstanding as of June 30, 2016 Class E Warrants 3,576,737 - - - (3,576,737 ) - Class F Warrants 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 4,012,289 - - - 4,641,667 Class K Warrants 3,310,000 1,890,000 - - - 5,200,000 Class L Warrants - 33,018,337 - - - 33,018,337 Class M Warrants - 1,943,333 - - - 1,943,333 Series A Warrants 25,951,421 - - (23,701,427 ) - 2,249,994 38,302,686 40,863,959 - (23,701,427 ) (3,576,737 ) 51,888,481
Schedule Of Warrant Exercise Price And Expiration Date [Table Text Block]	Exercise price/share Expiration date Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.06 February 2019 Class K Warrants $ 0.08 June 2025 Class L Warrants $ 0.08 March 2019 Class M Warrants $ 0.06 February 2021 Series A Warrants $ 0.06 March 2019
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Class J Warrants Class K Warrants Class M Warrants Series A Warrants Total Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ 138,100 Issued - - 75,422 - 75,422 Change in fair value 17,600 (6,600 ) 878 (102,600 ) (90,722 ) Warrant liability as of March 31, 2016 $ 20,500 $ 16,100 $ 76,300 $ 9,900 $ 122,800 Issued - 25,350 - - 25,350 Change in fair value (6,600 ) (16,150 ) (2,400 ) (3,100 ) (28,250 ) Warrant liability as of June 30, 2016 $ 13,900 $ 25,300 $ 73,900 $ 6,800 $ 119,900

Note 13 - Stock-based Compens25

Note 13 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 Weighted average expected life in years 5.0 5.5 Weighted average risk free interest rate 1.10 % 2.41 % Weighted average volatility 140.0 % 136.1 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 10,073,385 $ 0.62 Granted - $ - Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 10,073,385 $ 0.55 Granted 3,300,000 $ 0.04 Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of June 30, 2016 13,373,385 $ - Exercisable 13,273,385 $ 0.43
Schedule of Other Share-based Compensation, Activity [Table Text Block]	Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 175,002 $ 0.36 Granted - $ - Vested - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 175,002 $ 0.36 Granted 3,300,000 $ 0.04 Vested (3,375,002 ) $ 0.05 Cancelled - $ - Forfeited or expired - $ - Outstanding as of June 30, 2016 100,000 $ 0.21

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Retained Earnings (Accumulated Deficit)	$ (95,841,107)		$ (95,841,107)		$ (92,994,408)
Cash and Cash Equivalents, at Carrying Value	122,948	$ 1,615,727	122,948	$ 1,615,727	152,930	$ 3,547,071
Net Cash Provided by (Used in) Operating Activities			(1,731,124)	(1,917,858)
Net Income (Loss) Attributable to Parent	$ (1,122,123)	$ (1,521,533)	$ (2,846,699)	$ (2,680,648)	$ (4,810,285)

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Amortization of Intangible Assets	$ 76,689	$ 76,689	$ 153,378	$ 153,378

Note 4 - Summary of Intangible

Note 4 - Summary of Intangible Assets (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Patents, at cost	$ 3,502,135	$ 3,502,135
Less accumulated amortization	(3,348,757)	(3,195,379)
Net intangible assets	$ 153,378	$ 306,756

Note 5 - Summary of Accrued Exp

Note 5 - Summary of Accrued Expenses (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accrued former executive payment	$ 100,000	$ 100,000
Accrued audit and tax preparation	46,752	93,500
Accrued directors and advisors fees	45,333
Accrued outside services	43,105	58,813
Accrued legal professional fees	30,500	76,500
Accrued clinical study expenses	13,650	22,777
Accrued other	16,483	7,784
	$ 295,823	$ 359,374

Note 6 - Notes Payable, Relat30

Note 6 - Notes Payable, Related Parties (Details Textual) - USD ($)	Jun. 28, 2016	Aug. 01, 2015	Jun. 15, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jan. 13, 2016	Dec. 31, 2015
Health Tronics, Inc [Member] | Note Amendment [Member]
Related Party Transaction, Rate		2.00%	8.00%
Related Party, Notes Payable Manditory Prepayment Rate			20.00%
Health Tronics, Inc [Member] | Class K Warrants [Member]
Class of Warrant or Right, Issued During Period	1,890,000		3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08		$ 0.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1
Class of Warrant or Right, Expiration Period			10 years
Health Tronics, Inc [Member]
Related Party Transaction, Rate						6.00%
Notes Payable, Related Parties, Noncurrent				$ 5,334,234		$ 5,334,234			$ 5,348,112
Debt Instrument, Unamortized Discount				38,509		38,509			24,631
Common Stock, Par or Stated Value Per Share			$ 0.001
Interest Payable, Current				108,224		108,224			$ 239,803
Interest Expense, Related Party				$ 108,224	$ 80,968	$ 260,937	$ 161,039
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.08		$ 0.08
Class of Warrant or Right, Issued During Period						40,863,959
Common Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001		$ 0.001	$ 0.001

Note 7 - Promissory Notes Pay31

Note 7 - Promissory Notes Payable (Details Textual)	Feb. 01, 2016USD ($)shares	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
8% Convertible Promissory Notes [Member] | During First Sixty Days [Member]
Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance	120.00%
8% Convertible Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 58,300
Proceeds from Each Convertible Debt, Gross	$ 53,000
Debt Instrument, Original Issuance Discount Percent	10.00%
Number Of Investors	2
Proceeds from Convertible Debt	$ 106,000
Debt Instrument, Prepayment Term	60 days
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	30.00%
Debt Instrument, Convertible, Threshold Trading Days	20
Debt Instrument, Term	180 days
Notes Payable, Current		$ 115,933
Debt Issuance Costs, Net		4,473
Class M Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares	1
Proceeds from Convertible Debt		106,000
Notes Payable, Current		$ 115,933

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual)	Jun. 30, 2016USD ($)
Operating Loss Carryforwards	$ 70,096,802

Note 9 - Equity Transactions (D

Note 9 - Equity Transactions (Details Textual)	Apr. 15, 2016USD ($)shares	Apr. 06, 2016USD ($)shares	Mar. 11, 2016USD ($)$ / sharesshares	Jan. 13, 2016$ / sharesshares	Jun. 30, 2016$ / sharesshares	Dec. 31, 2015$ / shares	Jun. 15, 2015$ / shares
The 2016 Equity Offering [Member] | Health Tronics, Inc [Member]
Related Party, Notes Payable Manditory Prepayment Rate			20.00%
The 2016 Equity Offering [Member] | Class L Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
The 2016 Equity Offering [Member] | Class L Warrants [Member]
Class of Warrant or Right, Issued During Period			30,016,670
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.08
The 2016 Equity Offering [Member]
Stock Issued During Period, Shares, New Issues	1,437,501	3,083,334	25,495,835
Proceeds from Issuance of Private Placement Gross | $	$ 86,200	$ 185,000	$ 1,529,750
Health Tronics, Inc [Member]
Common Stock, Par or Stated Value Per Share | $ / shares							$ 0.001
Class L Warrants [Member] | Newport Coast Securities, Inc. and Oppenheimer & Co. Inc. [Member] | The 2016 Equity Offering [Member]
Class of Warrant or Right, Issued During Period					3,001,667
Class L Warrants [Member]
Class of Warrant or Right, Issued During Period					33,018,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 0.08
Series A Warrants [Member] | Convertible Common Stock [Member]
Stock Issued During Period, Shares, New Issues				7,447,954
Warrants Converted During Period				23,701,428
Convertible Preferred Stock, Shares Issued upon Conversion				12,500
Series A Warrants [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues				293
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.06		$ 0.06
Class of Warrant or Right, Exchange Ratio				0.4685
Common Stock, Ownership Threshold				9.99%
Subscription Agreement [Member] | On or before May 27, 2014 [Member]
Minimum Installment Amount Of Purchase Price | $			$ 100,000
Class of Warrant or Right, Issued During Period					40,863,959
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 0.001

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Apr. 29, 2016	Jan. 13, 2016	Mar. 17, 2014	Jun. 30, 2016	Jan. 12, 2016	Jan. 06, 2016	Dec. 31, 2015	Mar. 14, 2014
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	0			293			0
Preferred Stock, Shares Authorized				293			293
Preferred Stock, Par or Stated Value Per Share				$ 0.001			$ 0.001
Conversion of Stock, Shares Converted	293
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding						0
Preferred Stock, Shares Authorized								6,175
Preferred Stock, Par or Stated Value Per Share								$ 0.001
Preferred Stock, Stated Value Per Share								$ 1,000
Stock Issued During Period, Shares, New Issues			6,175
Undesignated Preferred Stock [Member] | Maximum [Member]
Preferred Stock, Shares Authorized				5,000,000
Undesignated Preferred Stock [Member]
Preferred Stock, Shares Outstanding				0			0
Preferred Stock, Shares Authorized				4,993,532			4,993,532
Preferred Stock, Par or Stated Value Per Share				$ 0.001			$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized					293
Preferred Stock, Par or Stated Value Per Share					$ 0.001
Preferred Stock, Stated Value Per Share					$ 1,000
Stock Issued During Period, Shares, New Issues		293
Convertible Preferred Stock, Shares Issued upon Conversion				2,000
Convertible Preferred Stock Beneficial Ownership Limitation Conversion Percentage				9.99%
Common Stock [Member]
Conversion of Stock, Shares Issued	3,657,278
Preferred Stock, Par or Stated Value Per Share		$ 0.001

Note 11 - Warrants (Details Tex

Note 11 - Warrants (Details Textual) - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Mar. 11, 2016	Feb. 01, 2016	Dec. 31, 2015	Jun. 15, 2015	Mar. 17, 2014	Feb. 10, 2014
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06		$ 0.06
Warrants and Rights Outstanding		$ 9,900			$ 112,500
Class J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06
Warrants and Rights Outstanding	$ 13,900	20,500			2,900			$ 12,776
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Warrants and Rights Outstanding	$ 25,300	16,100			22,700	$ 36,989
Class M Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06
Warrants and Rights Outstanding	$ 73,900	76,300		$ 9,091
Series A and B Warrants [Member] | 18% Convertible Promissory Notes [Member]
Warrants and Rights Outstanding								$ 47,974
Series A and B Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding							$ 557,733
8% Convertible Promissory Notes [Member]
Conversion Option of Debt Issued, Fair Value Disclosure				$ 66,331
Debt Instrument, Interest Rate, Stated Percentage				8.00%
18% Convertible Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage								18.00%
Warrants and Rights Outstanding	$ 119,900	$ 122,800			$ 138,100

Note 11 - Warrant Activity (Det

Note 11 - Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2016shares
Class E Warrants [Member]
Warrants Outstanding (in shares)	3,576,737
Warrants Expired (in shares)	(3,576,737)
Warrants Outstanding (in shares)
Class F Warrants [Member]
Warrants Outstanding (in shares)	300,000
Warrants Outstanding (in shares)	300,000
Class G Warrants [Member]
Warrants Outstanding (in shares)	1,503,409
Warrants Outstanding (in shares)	1,503,409
Class H Warrants [Member]
Warrants Outstanding (in shares)	1,988,095
Warrants Outstanding (in shares)	1,988,095
Class I Warrants [Member]
Warrants Outstanding (in shares)	1,043,646
Warrants Outstanding (in shares)	1,043,646
Class J Warrants [Member]
Warrants Outstanding (in shares)	629,378
Warrants Outstanding (in shares)	4,641,667
Warrants Issued (in shares)	4,012,289
Class K Warrants [Member]
Warrants Outstanding (in shares)	3,310,000
Warrants Outstanding (in shares)	5,200,000
Class L Warrants [Member]
Warrants Outstanding (in shares)	33,018,337
Warrants Issued (in shares)	33,018,337
Class M Warrants [Member]
Warrants Outstanding (in shares)	1,943,333
Warrants Issued (in shares)	1,943,333
Series A Warrants [Member]
Warrants Outstanding (in shares)	25,951,421
Warrants Outstanding (in shares)	2,249,994
Warrants Converted (in shares)	(23,701,427)
Warrants Outstanding (in shares)	38,302,686
Warrants Expired (in shares)	(3,576,737)
Warrants Outstanding (in shares)	51,888,481
Warrants Issued (in shares)	40,863,959
Warrants Converted (in shares)	(23,701,427)

Note 11 - Warrant Exercise Pric

Note 11 - Warrant Exercise Price Per Share and Expiration Date (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016	Mar. 11, 2016
Class E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Expiration date	April 2,016
Class F Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.35
Expiration date	February 2,018
Class G Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class H Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.85
Expiration date	September 2,018
Class J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06
Expiration date	February 2,019
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Expiration date	June 2,025
Class L Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Expiration date	March 2,019
Class M Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06
Expiration date	February 2,021
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	$ 0.06
Expiration date	March 2,019

Note 11 - Changes in the Warran

Note 11 - Changes in the Warrant Liability (Details) - USD ($)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Feb. 01, 2016	Jun. 15, 2015	Feb. 10, 2014
Class J Warrants [Member]
Warrant liability	$ 20,500	$ 2,900
Issued
Change in fair value	(6,600)	17,600
Warrants and Rights Outstanding	20,500	2,900			$ 12,776
Warrant liability	13,900	20,500
Class K Warrants [Member]
Warrant liability	16,100	22,700
Issued	25,350
Change in fair value	(16,150)	(6,600)
Warrants and Rights Outstanding	16,100	22,700		$ 36,989
Warrant liability	25,300	16,100
Class M Warrants [Member]
Warrant liability	76,300
Issued		75,422
Change in fair value	(2,400)	878
Warrants and Rights Outstanding	76,300		$ 9,091
Warrant liability	73,900	76,300
Series A Warrants [Member]
Warrant liability	9,900	112,500
Issued
Change in fair value		(102,600)
Warrants and Rights Outstanding	9,900	112,500
Warrant liability		9,900
Class A Warrants [Member]
Issued
Change in fair value	(3,100)
Warrants and Rights Outstanding	6,800
Warrant liability	6,800
Warrant liability	122,800	138,100
Issued	25,350	75,422
Change in fair value	(28,250)	(90,722)
Warrants and Rights Outstanding	122,800	138,100
Warrant liability	$ 119,900	$ 122,800

Note 12 - Commitments and Con39

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating Leases, Rent Expense, Net	$ 40,455	$ 38,505	$ 82,974	$ 71,912

Note 13 - Stock-based Compens40

Note 13 - Stock-based Compensation (Details Textual) - USD ($)	Jun. 16, 2016	Nov. 01, 2010	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Stock Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Stock Incentive Plan [Member] | Two Medical Advisory Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.0335
Allocated Share-based Compensation Expense	$ 110,550
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			12,500,000			12,500,000		12,500,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit						$ 0.04		$ 0.04
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit						$ 2		$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			$ 0			$ 0		$ 0
Allocated Share-based Compensation Expense			$ 112,050		$ 22,235	$ 116,550	$ 50,062
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term						7 years 229 days		7 years 167 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			3,300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.04

Note 13 - Fair Value Assumption

Note 13 - Fair Value Assumptions (Details)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Weighted average expected life in years	5 years	5 years 182 days
Weighted average risk free interest rate	1.10%	2.41%
Weighted average volatility	140.00%	136.10%
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note 13 - Summary of Options Ac

Note 13 - Summary of Options Activity (Details) - USD ($)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Outstanding, number (in shares)	10,073,385	10,073,385
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.55	$ 0.62
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.04
Forfeited or expired, number (in shares)
Forfeited or expired, weighted average exercise price per share
Outstanding, number (in shares)	13,373,385	10,073,385
Outstanding, weighted average exercise price per share (in dollars per share)		$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,300,000
Exercisable, number (in shares)	13,273,385
Exercisable (in dollars per share)	$ 0.43

Note 13 - Nonvested Options Act

Note 13 - Nonvested Options Activity (Details) - $ / shares	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Outstanding, number (in shares)	175,002	175,002
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.36	$ 0.36
Granted, number (in shares)	3,300,000
Vested, number (in shares)	3,375,002
Outstanding, number (in shares)	100,000	175,002
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.21	$ 0.36
Granted, weighted average exercise price per share (in dollars per share)	$ 0.04
Vested, number (in shares)	(3,375,002)
Vested, weighted average exercise price per share (in dollars per share)	$ 0.05

Note 14 - Earnings (Loss) Per44

Note 14 - Earnings (Loss) Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65,261,866	45,609,516

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual)	Aug. 15, 2016USD ($)	Aug. 09, 2016USD ($)$ / sharesshares	Jul. 29, 2016USD ($)shares	Feb. 01, 2016USD ($)	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Aug. 11, 2016$ / shares$ / itemshares	Jan. 13, 2016$ / shares	Dec. 31, 2015$ / shares
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Conversion if Company is DWAC Operational [Member]
Conversion Price, Percentage from Lowest Closing Price of Common Stock			70.00%
Number of Trading Days Preceding the Debentures Conversion Date			20 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Conversion if not DWAC Operational or Common Stock Trades on Bottom Tier OTC Pink [Member]
Conversion Price, Percentage from Lowest Closing Price of Common Stock			65.00%
Number of Trading Days Preceding the Debentures Conversion Date			20 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period One [Member] | Maximum [Member]
Number of Days from Debt Debentures Issuance Date			90 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period One [Member]
Redemption Price, Percentage from Sum of Principal Amount Redeemed Plus Accrued Interest			105.00%
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Two [Member] | Maximum [Member]
Number of Days from Debt Debentures Issuance Date			120 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Two [Member] | Minimum [Member]
Number of Days from Debt Debentures Issuance Date			91 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Two [Member]
Redemption Price, Percentage from Sum of Principal Amount Redeemed Plus Accrued Interest			115.00%
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Three [Member] | Maximum [Member]
Number of Days from Debt Debentures Issuance Date			150 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Three [Member] | Minimum [Member]
Number of Days from Debt Debentures Issuance Date			121 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Three [Member]
Redemption Price, Percentage from Sum of Principal Amount Redeemed Plus Accrued Interest			120.00%
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Four [Member] | Maximum [Member]
Number of Days from Debt Debentures Issuance Date			180 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Four [Member] | Minimum [Member]
Number of Days from Debt Debentures Issuance Date			151 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Four [Member]
Redemption Price, Percentage from Sum of Principal Amount Redeemed Plus Accrued Interest			130.00%
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Five [Member] | Minimum [Member]
Number of Days from Debt Debentures Issuance Date			181 days
Convertible Debentures [Member] | Subsequent Event [Member] | Debt Instrument, Redemption, Period Five [Member]
Redemption Price, Percentage from Sum of Principal Amount Redeemed Plus Accrued Interest			140.00%
Convertible Debentures [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount			$ 500,000
Proceeds from Convertible Debt			$ 450,000
Original Issue Discount, Percentage			10.00%
Number of Accredited Investors			1
Debt Instrument, Fee Amount			$ 2,500
Debt Instrument, Shares, Commitment Fee | shares			835,000
Number of Days from Debt Debentures Issuance Date			151 days
Maximum Number of Days of Written Notice to Call Debt			2 days
Convertible Debentures, Tranche One [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount			$ 200,000
Proceeds from Convertible Debt			175,000
Debt Instrument, Fee Amount			2,500
Debt Instrument, Unamortized Discount			20,000
Debt Issuance Costs, Gross			$ 2,500
Convertible Promissory Note [Member] | Subsequent Event [Member]
Repayments of Notes Payable	$ 58,300
8% Convertible Promissory Notes [Member] | Subsequent Event [Member]
Prepayment Penalty Percentage	140.00%
8% Convertible Promissory Notes [Member]
Debt Instrument, Face Amount				$ 58,300
Proceeds from Convertible Debt				$ 106,000
Subsequent Event [Member] | Private Placement [Member] | Class L Warrants [Member]
Class of Warrant or Right, Issued During Period | shares		0
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues | shares		0
Stock Issued During Period, Value, New Issues		$ 0
Subsequent Event [Member] | Placement Agent [Member] | Class L Warrants [Member]
Class of Warrant or Right, Issued During Period | shares		0
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares		$ 130,000
Subsequent Event [Member] | 2016 Private Placement [Member]
Purchase Price of Unit | $ / item							0.06
Common Stock, Par or Stated Value Per Share | $ / shares							$ 0.001
Common Stock Per Unit | shares							1
Warrant Per Unit | shares							1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 0.08
Class L Warrants [Member]
Class of Warrant or Right, Issued During Period | shares					33,018,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 0.08
Proceeds from Convertible Debt					$ 106,000
Class of Warrant or Right, Issued During Period | shares					40,863,959
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.001			$ 0.001	$ 0.001